CN1466460A - 膳食纤维对人和脊椎动物的全身性感染的抑制作用 - Google Patents
膳食纤维对人和脊椎动物的全身性感染的抑制作用 Download PDFInfo
- Publication number
- CN1466460A CN1466460A CNA018165524A CN01816552A CN1466460A CN 1466460 A CN1466460 A CN 1466460A CN A018165524 A CNA018165524 A CN A018165524A CN 01816552 A CN01816552 A CN 01816552A CN 1466460 A CN1466460 A CN 1466460A
- Authority
- CN
- China
- Prior art keywords
- dietary fiber
- fiber
- inulin
- vertebrates
- levan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013325 dietary fiber Nutrition 0.000 title claims abstract description 54
- 230000009885 systemic effect Effects 0.000 title claims abstract description 29
- 241000251539 Vertebrata <Metazoa> Species 0.000 title claims abstract description 28
- 230000005764 inhibitory process Effects 0.000 title abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 46
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 43
- 229920001202 Inulin Polymers 0.000 claims abstract description 42
- 229940029339 inulin Drugs 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 33
- 208000015181 infectious disease Diseases 0.000 claims abstract description 26
- 241000251468 Actinopterygii Species 0.000 claims abstract description 15
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 7
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 241000723343 Cichorium Species 0.000 claims abstract 5
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 37
- 239000000835 fiber Substances 0.000 claims description 20
- 150000002482 oligosaccharides Chemical class 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 235000019621 digestibility Nutrition 0.000 claims description 15
- 239000001913 cellulose Substances 0.000 claims description 14
- 229920002678 cellulose Polymers 0.000 claims description 14
- 235000019688 fish Nutrition 0.000 claims description 13
- 229920001542 oligosaccharide Polymers 0.000 claims description 12
- 238000006116 polymerization reaction Methods 0.000 claims description 9
- 230000000813 microbial effect Effects 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 229920005610 lignin Polymers 0.000 claims description 5
- 229920002488 Hemicellulose Polymers 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 241000881711 Acipenser sturio Species 0.000 claims description 3
- 241000972773 Aulopiformes Species 0.000 claims description 3
- 241000252233 Cyprinus carpio Species 0.000 claims description 3
- 241000157468 Reinhardtius hippoglossoides Species 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 241001233037 catfish Species 0.000 claims description 3
- 229920001206 natural gum Polymers 0.000 claims description 3
- 235000019515 salmon Nutrition 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 abstract description 6
- 230000003405 preventing effect Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract 3
- 229920002670 Fructan Polymers 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 26
- 210000000936 intestine Anatomy 0.000 description 24
- 210000002784 stomach Anatomy 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 20
- 235000013305 food Nutrition 0.000 description 20
- 244000052769 pathogen Species 0.000 description 19
- 230000001717 pathogenic effect Effects 0.000 description 19
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 241000186781 Listeria Species 0.000 description 14
- 206010020718 hyperplasia Diseases 0.000 description 13
- 210000001616 monocyte Anatomy 0.000 description 13
- 229930091371 Fructose Natural products 0.000 description 12
- 239000005715 Fructose Substances 0.000 description 12
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 12
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 241000607142 Salmonella Species 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 206010040047 Sepsis Diseases 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000013223 septicemia Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000006161 blood agar Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000019331 Foodborne disease Diseases 0.000 description 3
- 240000008892 Helianthus tuberosus Species 0.000 description 3
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000020940 control diet Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 244000298479 Cichorium intybus Species 0.000 description 2
- 244000115658 Dahlia pinnata Species 0.000 description 2
- 235000012040 Dahlia pinnata Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000005993 intestine dysfunction Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000004682 mucosal barrier function Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000011833 salt mixture Substances 0.000 description 2
- 230000005985 stomach dysfunction Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 206010061393 typhus Diseases 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- OIDPCXKPHYRNKH-UHFFFAOYSA-J chrome alum Chemical compound [K]OS(=O)(=O)O[Cr]1OS(=O)(=O)O1 OIDPCXKPHYRNKH-UHFFFAOYSA-J 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000854 inhibitional effect Effects 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000011656 manganese carbonate Substances 0.000 description 1
- 235000006748 manganese carbonate Nutrition 0.000 description 1
- 229940093474 manganese carbonate Drugs 0.000 description 1
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 description 1
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004051 menadione sodium bisulfite Drugs 0.000 description 1
- XDPFHGWVCTXHDX-UHFFFAOYSA-M menadione sodium sulfonate Chemical compound [Na+].C1=CC=C2C(=O)C(C)(S([O-])(=O)=O)CC(=O)C2=C1 XDPFHGWVCTXHDX-UHFFFAOYSA-M 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Fodder In General (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了使用膳食纤维或膳食纤维的混合物生产一种组合物,诸如药物组合物、功能性食物和功能性饲料,以防止、抑制和/或治疗由病原菌引起的人和脊椎动物的全身性感染的用途。还公开了一种防止和/或抑制人或脊椎动物中病原菌的全身性生长的方法,和一种防止、抑制和/或治疗人或脊椎动物中由病原菌引起的全身性感染的方法,该方法包括给所述的人或脊椎动物给与一种含有效量的膳食纤维或膳食纤维的混合物的组合物。该膳食纤维优选的是果聚糖,特别是菊糖和/或寡果糖,最优选的是平均聚合度(DP)至少为20的菊苣菊糖。这种组合物及方法用于防止、抑制和/或治疗由病原菌引起的鱼的全身性感染,尤其是在鱼场鱼养殖期间。
Description
发明领域
本发明涉及一种膳食纤维的用途,尤其是一种果聚糖用于生产一种组合物以防止和/或抑制人和脊椎动物中病原菌的全身性生长。本发明还涉及一种方法以防止和/或抑制人和脊椎动物中病原菌的全身性生长,以及涉及一种方法,该方法通过给与含有一种膳食纤维(尤其是一种果聚糖),防止、抑制和/或治疗人和脊椎动物中的全身性感染。
背景技术
膳食纤维是一个通用术语,用于描述那些人体和脊椎动物消化道不能消化的食物成份(在此用术语非消化性简称)。过去,膳食纤维被认为主要由木质素、纤维素、半纤维素或果胶组成。但是,最近其它的膳食纤维,诸如非消化性淀粉和非消化性果聚糖,包括左聚糖、菊糖和寡糖,引起了人们的广泛关注。
膳食纤维的来源十分广泛,可包括树(纤维素)、来自糖甜菜的甜菜浆、植物的提取物、植物各部分和果实,如阿拉伯胶、果聚糖,包括来源于梯牧草(Phleam pratense)的果聚糖、菊糖和果聚寡糖(也称为寡果糖)、菊苣的根、大丽花和耶路撒冷蓟(Jerusalem artichoke)的块茎;来自水果的柑橘果胶;来自海藻的角叉胶和来自果核的壳(如花生皮)。虽然在传统上非消化性寡糖不被认为是膳食纤维,但它们满足必需的指标,现在通常已被认为是膳食纤维。非消化性寡糖和多糖也可从微生物生产(如果聚寡糖、左聚糖和菊糖),也可通过酶法合成获得,如由蔗糖制备果聚寡糖。通过非消化性多糖的部分水解也可获得非消化性寡糖,例如通过果聚糖的部分酸或酶水解获得果聚寡糖。术语果聚寡糖和寡果糖在本文中为同一概念。
果聚糖,即左聚糖和菊糖一般以具有不同链长的碳水化合物的混合物的形式存在,而且这些碳水化合物大部分由呋喃型的果糖作为主要连接形式。事实上,果聚寡糖或寡果糖是指由小于10个糖单位的分子组成的,它可通过以下途径获得,即从植物原料的提取,果聚糖、尤其是菊糖的部分水解(酸水解或酶水解)及由蔗糖的酶法合成获得。所有这些类型的果聚糖在本文中统称果聚糖。
果聚糖,包括左聚糖、菊糖和寡果糖在本领域是熟知的,且被认为是膳食纤维。左聚糖由果糖主要或仅仅通过β(2-6)链连接而成,要么含有一个或不含末端葡萄糖。菊糖由果糖主要或仅仅通过β(2-1)链连接而成。大部分菊糖链以单个葡萄糖作为末端,但并不是缺少不可,左聚糖大部分以支链的果糖链的形式存在,而菊糖是由直链的果糖组成,但它在某种程度上也可以存在由果糖组成的分枝链。所有所述的果聚糖,即左聚糖、菊糖和寡果糖在本发明中都具有一致性(即通用性)。
菊糖在新鲜菊苣、大理花和耶路撒冷蓟块茎中约占10-20%(重量比),按照已知技术可在工业规模上分离和纯化菊糖,且有诸多途径选择性地除去杂质和不需要的碳水化合物的组份。
菊糖可用通式GFn和Fm表示,G代表葡萄糖单位,F代表果糖单位,n代表连接于末端葡萄糖上的果糖数目,m代表在碳水化合物链上相互连接的果糖的个数。在一个果聚糖分子中的糖的个数(果糖和葡萄糖单元),即以上公式中的值n+1和m,通常指聚合度,由(
DP)表示。菊糖的另外的特征是平均聚合度(数量),由(
DP)表示,是指每种多糖(菊糖)分子糖单元的数目。
菊苣来源的菊糖在市场上购得,如ORAFTI生产的商品名RAFTILINE(蒂嫩,比利时),有各种级别,例如ST(具有(
DP)约为10,且含有8%重量比的葡萄糖、果糖和蔗糖),LS(具有(
DP)约为10,但含有少于1%重量比的葡萄糖、果糖和蔗糖),和HP(具有(
DP)≥23,通常约25,含小于1%重量比的葡萄糖、果糖和蔗糖)。
果聚寡糖(寡果糖)由小于10个果糖单元的链组成,主要或仅仅通过β(2-6)链或β(2-1)链互相连接,可存在一个末端葡萄糖基。
寡果糖可以从市场上购得,例如ORAFTI生产的商品名RAFTILOSE(蒂嫩,比利时),有各种级别,例如RAFTILOSEP95,约含95%(重量比)的寡果糖,由聚合度约为2-7的链组成,通常(
DP)为3.5-4.5,且含有5%(重量比)的葡萄糖、果糖、蔗糖。
可根据其在水中的溶解性来分类膳食纤维,也可根据膳食纤维是否能被肠胃道细菌用作能源来分类,即膳食纤维能否被肠胃道细菌进行代谢(发酵)。可被肠胃道细菌利用的纤维被认为是可发酵的。术语可发酵的纤维和膳食纤维在本文可交换使用。
膳食纤维似乎与改善人和动物的健康状况有关联。人和脊椎动物的肠胃道含有许多种细菌,一些通常存在的细菌被认为是有益的,而通常在细菌感染情况下在肠道中存在的另一些细菌被认为是病原菌。术语病原菌一般包括病原菌及腐败菌。
有益细菌具有产生乳酸、其它短链脂肪酸、代谢物和其它化合物的能力。而这些化合物已被公认为对某些身体功能具有有益的作用,而且能抑制肠胃道中病原菌的生长,这种有益作用的过程称为抑制。摄取膳食纤维,尤其是菊糖和非消化性寡糖(如寡果糖)能促进有益细菌(如双岐杆菌和乳酸杆菌)的生长,从而导致对宿主的各种有益的作用,包括如在人体中,随着便秘的减少,增加粪便重量和粪便频率,降低血糖反应的影响,降低对血胆固醇、高密度脂蛋白(HDL)/低密度脂蛋白(LDL)比率及血清脂质的影响。进一步的作用包括免疫调节作用,尤其是导致对人和脊椎动物的癌症(特别是乳房癌和结肠癌)有预防、抑制和/或治疗作用。肠胃道的有益细菌通常包括双岐杆菌属和乳酸杆菌属。
病原菌可使宿主引起各种疾病和功能不良,包括腹泻和传染病,如小肠结肠炎、肠胃道溃疡和克罗恩病。
已知有益细菌,尤其双岐杆菌属和乳酸杆菌属的那些细菌具有发酵膳食纤维(一般是果聚糖和非消化性寡糖)的能力比病原性肠道细菌更强。摄取膳食纤维,尤其是果聚糖和/或非消化性寡糖,增加肠胃道中产乳酸细菌的密度而减少不需要的肠杆菌的数量。后者包括大多数病原菌,例如梭菌属、拟杆菌属、李斯忒菌属、念珠菌属和沙门氏菌属的细菌。困此,膳食纤维(如果聚糖和/或寡果糖)的摄取可用来选择性地促进肠胃道中有益菌的生长。改进有益菌/病原菌的比例从而对宿主产生有益的健康作用。
现在可以采用一些方法从而防止、控制和/或治疗由病原菌直接或间接引起的人和脊椎动物的肠胃道功能紊乱和疾病。第一种方法是摄取能选择性地去除靶细菌的抗生素。第二种方法是摄取益生菌(活的有益菌),如双岐杆菌和乳酸杆菌,能改变肠胃道菌群的组成和代谢,从而对宿营主健康起有益的作用。第三种方法是摄入益生素(即膳食纤维),同时使不需要的病原菌和腐败菌减少,其增加了肠胃道中有益菌/病原菌的比例,从而对宿主产生有益的健康作用,例如允许较快恢复粘膜量和消化能力,抑制和/或缓解肠胃道功能不全和疾病。在第四种方法中,凝集素,某些单糖(如甘露糖)和某些有机酸(如单、二和三羧酸)已用于选择性地减少一些病原菌的密度。
肠胃道功能不良和疾病(如腹泻和胃肠炎)通常导致粘膜屏障的破坏,该粘膜屏障的破坏增加细菌从肠胃道转移到肠系膜淋巴结和血流的危险,常在宿主中引起败血症。但是,细菌渗入血流或另一体液不仅通过一种被破坏的肠胃道粘膜,而且通过对屏障的任何形式的破坏、衰弱或引起其功能不良来实现,这些屏障,如鱼的鳃或皮肤,从而可在宿主中引起败血症。由穿过宿主的屏障的细菌引起的败血症按常规和在下文称为全身性感染。
现在,通常对感染的宿主给与抗生素来抑制和治疗所述的败血症。此外,为了控制病原菌的生长和肠胃道的感染,以及防止脊椎动物中由所述的病原菌引起后来的全身性败血症,通常在饲料中添加抗生素。
然而,由于细菌菌株对抗生素产生抗药性和它们对环境的潜在影响,所以人们愈来愈关心抗生素的使用。用一些抗生素治疗的另一危害是破坏正常的肠胃道细菌菌群。
因此,人们正在寻找防止、抑制和治疗全身性细菌感染的化合物和方法,目前在这方面使用的化合物和方法存在一种或多种缺点。
发明内容
在研究摄取可发酵的纤维对人和脊椎动物的影响的期间,发明人发现口服给药(包括通过管饲给药)和/或直肠给与膳食纤维,尤其是菊糖和寡糖,不但能通过促进有益菌的生长和通过改进有益菌/病原菌比例影响肠胃道菌群,而且惊奇的是,还能使宿主对由病原菌引起的全身性感染的反应产生有益的影响。
所述的发现产生了本发明,在一方面本发明涉及使用一种膳食纤维或膳食纤维的混合物生产一种组合物,例如一种药物组合物或一种功能性食物组合物或一种功能性饲料组合物,用于防止、抑制和/或治疗人和脊椎动物中由病原菌引起的全身性感染。按照常规技术可生产所述的组合物。
在另一方面,本发明涉及防止和/或抑制人和脊椎动物中病原菌全身性生长的方法,并提供防止、抑制和/或治疗人和脊椎动物中由病原菌引起的全身性感染的方法,包括对人和脊椎动物通过口服、管饲或直肠给与一种组合物(含有有效量的膳食纤维或膳食纤维的混合物的一种功能性食物组合物、一种功能性饲料组合物或一种药物组合物)。
附图说明
图1显示小鼠模型的数据。存活超过14天的小鼠是指用单核细胞增生李斯忒氏菌(Listeria monocytogenes)全身性感染的小鼠,喂饲的膳食包括1)纤维素;2)寡果糖;3)菊糖。
图2显示小鼠模型的数据。存活超过14天的小鼠是指用鼠伤寒少门氏菌(Salmonella Typhimurine)全身性感染的小鼠,喂饲的膳食包括(1)纤维素;(2)寡果糖;(3)菊糖。
具体实施方式
根据本发明,术语膳食纤维,本文也可交换称为可发酵的纤维。指一种可食的化合物,包括木质素、低聚碳水化合物和多聚碳水化合物,它们抗人和脊椎动物消化道的酶的水解作用。术语膳食纤维包括木质素、纤维素、半纤维素、果胶、树胶[如阿拉伯胶、角叉胶、蜡和非消化性寡糖,如寡果糖(此术语可用果聚寡糖交换使用)],和非消化性多糖(如非消化性泻粉和果聚糖),包括左聚糖和菊糖。优选的膳食纤维包括菊糖、低聚果糖以及它们的混合物;更优选的膳食纤维包括具有(
DP)至少为20的菊苣菊糖;最优选的是具有(
DP)至少为25的菊苣菊糖。
根据本发明,口服摄取和/或直肠摄取膳食纤维可防止、抑制和/或治疗人和脊椎动物中由病原菌引起的全身性感染。
术语口服给药/口服摄取在本文通常包括通过管饲给药。
所述的纤维可以一种药物组合物(药物)的形式与药学上可接受的赋形剂一起存在,可选择性地加入一种或多种具有附加生理活性物质。所述的药物通常以常规的草本制剂的形式存在,以确保它适合于口服给药、管饲或直肠给药,尤其如片剂、锭剂、胶囊、糖浆、悬浮液、乳剂、溶液和栓剂。
所述的纤维也可作为功能性食物组合物或功能性饲料组合物中的功能性成分存在,它们是一种食物或饲料的产品,可提供的健康益处超过传统的营养品。最好每天给与有效量的膳食纤维(以合适的组合物形式),每天剂量为单剂量形式或以二种或更多剂量形式。每天总的膳食纤维量可大不相同,这取决于纤维或纤维混合物和宿主的特性,以及针对如防止、抑制或治疗作用所取得的效果。最适日剂量通常与宿主能消耗的最大量相符合,而不产生明显的不良副作用,这些副作用一般是与摄取太大量的膳食纤维同时产生的,如肠胃胀气和腹泻。可在先前的文献中找到最适剂量和/或由熟练的人员通过常规实验来确定最适剂量。对成年人,菊糖和/或寡果糖的日剂量范围一般为5-40克/天,最适剂量范围一般为5-25克/天。
根据本发明,当给与人或脊椎动物一种膳食纤维或两种或更多膳食纤维的混合物(尤其是菊糖和/或寡果糖)时,已观察到对病原菌的全身性生长具有明显的防止或抑制作用。
对由病原菌引起的全身性感染很敏感的典型脊椎动物包括鱼而言,在鱼场养殖期间在鱼中会产生高的死亡率达80%,甚至更高的死亡率。因此根据本发明的组合物和方法对防止和抑制鱼中病原菌全身性生长是很有用的,并且可以防止、抑制和/或治疗鱼的全身性感染,例如鲑、鲟、鲇鱼、大菱鲆和鲤鱼,尤其是在鱼场鱼养殖期间。典型的方法为,根据本发明,给与鱼的饲料包括一种组合物,其含有一种膳食纤维或膳食纤维的混合物,尤其包括菊糖和/或是寡果糖。
此外,膳食纤维对宿主无毒性作用,不产生抗药性细菌菌株。而且,它们可通过可发挥各种如上所述有益作用的宿主的有益肠胃道细菌来发酵,因而它们不会危害环境。此外,可以经济的方式从可再生的资源中获得膳食纤维。因此,根据本发明膳食纤维可用于防止、抑制和/或治疗人和脊椎动物的全身性感染,比先前技术所采用的化合物(如抗生素)有很多的优点。
以下通过实施例说明本发明。
实施例1
实施例1涉及由单核细胞增生李斯忒氏菌引起的全身性感染,这种李斯忒菌属的典型病菌,可引起李斯忒菌病。在大多数严重病例中,李斯忒菌病的表征包括败血病、脑膜炎(或脑膜脑炎)、脑炎和引起孕妇子宫内或宫颈感染,可导致自然流产或死产。开始所述的病症前通常会出现流感样症状(包括头痛和持续发热),此外,肠胃道紊乱症状(如恶心、呕吐和腹泻)接着出现严重形式的李斯忒菌病或可能仅仅表现这种症状。
当从血液、脑脊液或其它正常无菌部位(如胎盘)中分离单核细增生李斯忒氏菌时,在临床上确定为李斯忒菌病。单核细胞增生李斯忒氏菌可侵入肠胃道上皮组织。一旦细菌进入宿主的单核细胞、巨噬细胞或多形核白细胞,它是血行传播的(败血病的),且可以生长。在吞噬细胞中,它在胞内存在也允许进入脑中,或许经胎盘转移到孕妇的胎内。在严重感染单核细胞增生李斯忒氏菌的4人中约有1人会死亡。
单核细胞增生李斯忒氏菌的病理基于其在吞噬的宿主细胞中存活和增殖的能力。
单核细胞增生李斯忒氏菌的培养
强毒EGD株的单核细胞增生李斯忒氏菌(Erdenlig,Ainsworth andAustin,J.Food protection,63,613-619,(2000))在血琼脂平板上,37℃生长24小时,富集细菌,使其悬浮于0.9%盐水,经离心(3,200×g;5分钟),再用0.9%盐水洗涤两次,再离心。沉积的细菌再悬浮于0.9%无菌盐水中。洗涤的细菌在振荡的胰蛋白
液体培养基中,37℃增殖过夜。将细菌悬浮液稀释至所需浓度(与1-5×107细菌/毫升所测的光密度相符)。这可通过血琼脂平板上的铺板数和计算得到的菌落来证实。
用单核细胞增生李斯忒氏菌感染B6F3FI小鼠
向25只小鼠腹膜内注射0.1毫升(1-5×106感染剂量)增殖的单核细胞增生李斯忒氏菌,在初步研究中确定了小鼠在感染该剂量的单核细胞增生李斯忒氏菌后,14天后会导致30-40%的死亡率。
膳食补加制剂的制备
所有膳食由Research Diets(新不伦瑞克,新泽西州)以小丸的形式制备。根据AIN76啮齿动物膳食给小鼠喂饲食物,其食物最终重量中含10%纤维(见表1)。对照食物含有10%不溶解的和发酵差的纤维素(结晶形)。实验小鼠(非对照组)的食物中,用能被肠胃道细菌发酵而且具有不同平均聚合度((
DP)分别在4-25之间)的寡果糖(RAFTILOSEP95;ORAFTI,比利时)或菊糖(RAFTILINEHP;ORAFTI,比利时)完全代替对照组小鼠食物中的纤维素。如表1所示,感染前给小鼠喂饲对照膳食和实验膳食6周。
表1
在用单核细胞增生李斯忒氏菌(实施例1)或鼠伤寒沙门氏菌(实施例2)感染前,给小鼠喂饲对照膳食和实验膳食的成分。在感染后,给小鼠继续喂饲膳食2周。
成分 | 克 |
酪蛋白,30目DL甲硫氨酸玉米淀粉蔗糖玉米胚芽油盐混合物S100012维生素混合物V100013二酒石酸胆碱纤维4 | 20031504505035102100 |
注:
1.由Research Diets公司(新不伦瑞克,新泽西州)配制和制备膳食,其是以AIN 76啮齿动物膳食为基础。
2.盐混合物(35克的量)的成分:二价磷酸钙(Ca=5.2克;P=4.0克),氧化镁(Mg=0.5克),柠檬酸钾(K=3.6克),硫酸钾(S=0.33克),硫酸铬钾(Cr=2.0毫克),氯化钠(Na=1.0克;Cl=1.6克),碳酸铜(Cu=6.0毫克),碘酸钾(I=0.2毫克),柠檬酸铁(Fe=45毫克),碳酸锰(Mn=59毫克),亚硒酸钠(Se=0.16毫克),碳酸锌(Zn=29毫克),以蔗糖补充至35克。
3.维生素混合物(10克的量)的成份:维生素A棕榈酸盐(4000国际单位),维生素D3(1000国际单位),维生素E乙酸盐(50国际单位),甲萘醌亚硫酸氢钠(0.5毫克甲萘醌),生物素(0.2毫克),氰钴胺素(10微克),叶酸(2毫克),烟酸(30毫克),泛酸钙(16毫克),吡哆素-HXI(7毫克),核黄素(6毫克),硫胺素盐酸(6毫克),以蔗糖补充至10g。
4、对照膳食含有作为唯一纤维来源的纤维素,而实验膳食含有100克菊糖或寡果糖。
图1显示实施例1的结果。从图1中显示的数据清楚地表明,当用单核细胞增生李斯忒氏菌全身感染时,用纤维素(一种不可发酵的纤维)食物喂饲的小鼠有28%死亡率。相反,用同样食物(但具有寡果糖)喂饲的小鼠死亡率较小(12%),菊糖甚至更有效(死亡率0%)。这些结果表明,补充寡糖和菊糖的膳食能防止一种已知病原菌的全身性感染。
实施例2
实施例2涉及由鼠伤寒沙门氏菌引起的小鼠全身性感染。
存在许多种沙门氏菌,有些引起食物传染的疾病。鼠伤寒沙门氏菌引起与沙门氏菌有关的大多数食物传染的疾病。最近另一种肠炎沙门氏菌(Salmonella enteritidis)与吃了污染未煮的鸡蛋引起食物传染的疾病有关,这种疾病是由沙门氏菌从肠腔侵入和通过小肠的上皮引起的(在那里出现炎症)。
鼠伤寒沙门氏菌的培养
鼠伤寒沙门氏菌(ATCC蓖株14024)在B6F3F1小鼠中传代3次以确保毒力。每次从死小鼠的脾培养鼠伤寒沙门氏菌。得到的强毒株用作代表性细菌病原菌。强毒鼠伤寒沙门氏菌在血琼脂平板上,37℃生长24小时。富集细菌,悬浮于0.9%盐水,经离心(3,200×g;5分钟),再用0.9%盐水洗涤两次,再离心。沉积的细菌悬浮于0.9%无菌盐水中。洗涤的细菌在振荡的胰蛋白
液体培养基中,37℃增殖过夜。将细菌悬浮液稀释至所需浓度(与1-2×104细菌/毫升所测的光密度相符)。这可通过血琼脂平板上的铺板数和计算得到的菌落来证实。
用鼠伤寒沙门氏菌感染B6F3FI小鼠
向25只小鼠腹膜内注射0.1毫升(1-5×103感染剂量)增殖的鼠伤寒少门氏菌,在初步研究中确定了小鼠在感染该剂量的鼠伤寒沙门氏菌后,14天后会导致70-80%的死亡率。
膳食补加制剂的制备
所有膳食由Research Diets(新不伦瑞克,新泽西州)以小丸的形式制备。用实施例1单核细胞增生李斯忒氏菌研究中的相同方法喂饲小鼠。根据AIN76啮齿动物膳食给小鼠喂饲食物,其食物最终重量中含10%纤维(见表1)。对照食物含有10%不溶解的和发酵差的纤维素。实验小鼠(非对照组)的食物中,用能被肠胃道细菌发酵而且具有不同平均聚合度((
DP)分别在4-25之间)的寡果糖(RAFTILOSEP95;ORAFTI,比利时)或菊糖(RAFTILINEHP;ORAFTI,比利时)完全代替对照组小鼠食物中的纤维素。
给小鼠喂饲对照食物和实验食物6周。
图2显示实施例2的结果。从图2中显示的数据清楚地表明,当用鼠伤寒沙门氏菌全身感染时,用纤维素(一种不可发酵的纤维)食物喂饲的小鼠有82%死亡率。相反,用同样食物(但具有寡果糖)喂饲的小鼠死亡率较小(75%),用菊糖喂饲的小鼠死亡率60%。
图2的数据表明,当感染鼠伤寒沙门氏菌时,用具有寡果糖和菊糖的食物喂饲的小鼠死亡率比用具有纤维素的食物喂饲的对照小鼠死亡率低。
这些结果提供了补充的证据,即寡果糖和菊糖增加了对全身性病原菌的抵抗力。
虽然参照附图,通过实施例充分描述了本发明,但值得注意的是各种变化和修改对于本领域熟练技术人员是显而易见的。因此,从以下权利要求,包括所有的等效形式(它们限定了本发明的范围)可理解前面的详细描述。
因此,这些变化和修改应该被解释为包括在本发明中,除非这些变化和修改脱离本发明的范围。
Claims (18)
1、使用膳食纤维或膳食纤维的混合物生产一种组合物以防止、抑制和/或治疗由病原菌引起的人和脊椎动物的全身性感染。
2、根据权利要求1所述的用途,其特征在于,该组合物选自药物组合物、功能性食物和功能性饲料。
3、根据权利要求1或2所述的用途,其特征在于,该组合物以适合给药的形式选自口服给药、管饲和直肠给药。
4、根据权利要求1或3任一所述的用途,其特征在于,该膳食纤维或膳食纤维的混合物选自木质素、纤维素、半纤维素、果胶、树胶、阿拉伯胶、角叉胶、蜡、非消化性寡糖、寡果糖、非消化性多糖、非消化性淀粉和果聚糖。
5、根据权利要求4所述的用途,其特征在于,该纤维是选自菊糖和寡果糖或其任何混合物的一种果聚糖。
6、根据权利要求5所述的用途,其特征在于,该纤维是菊苣菊糖,具有平均聚合度(
DP)至少为20。
7、根据权利要求5所述的用途,其特征在于,该纤维是菊苣菊糖,具有平均聚合度(
DP)至少为25。
8、根据权利要求1-7的任一所述的用途,其特征在于,该脊椎动物是鱼而且组合物是口服给药。
9、根据权利要求8所述的用途,其特征在于,该鱼选自鲑、鲟、鲇鱼、大菱鲆和鲤鱼。
10、防止、抑制和/或治疗人或脊椎动物中由病原菌引起的全身性感染的方法,其特征在于,该方法包括给所述的人或脊椎动物给与一种含有效量的膳食纤维或膳食纤维的混合物的组合物。
11、根据权利要求10所述的方法,其特征在于,该组合物是口服、管饲或直肠给药。
12、根据权利要求10所述的方法,其特征在于,该组合物选自药物组合物、功能性食物和功能性饲料。
13、根据权利要求10所述的方法,其特征在于,该膳食纤维或膳食纤维的混合物选取自木质素、纤维素、半纤维素、果胶、树胶、阿拉伯胶、角叉胶、蜡、非消化性寡糖、寡果糖、非消化性多糖、非消化性淀粉和果聚糖。
14、根据权利要求13所述的方法,其特征在于,该纤维是选自菊糖和寡果糖或其任何混合物的一种果聚糖。
15、根据权利要求14所述的方法,其特征在于,该纤维是菊苣菊糖,具有平均聚合度(
DP)至少为20。
16、根据权利要求14所述的方法,其特征在于,该纤维是菊苣菊糖,具有平均聚合度(
DP)至少为25。
17、根据权利要求10所述的方法,其特征在于,该脊椎动物是鱼而且组合物是口服给药。
18、根据权利要求17所述的方法,其特征在于,该鱼选自鲑、鲟、鲇鱼、大菱鲆和鲤鱼。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/671,106 US7431939B1 (en) | 2000-09-28 | 2000-09-28 | Inhibition of systemic infections in humans and vertebrates by dietary fibers |
US09/671,106 | 2000-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1466460A true CN1466460A (zh) | 2004-01-07 |
CN1315482C CN1315482C (zh) | 2007-05-16 |
Family
ID=24693153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018165524A Expired - Fee Related CN1315482C (zh) | 2000-09-28 | 2001-09-27 | 膳食纤维对人和脊椎动物的全身性感染的抑制作用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7431939B1 (zh) |
EP (1) | EP1320375B1 (zh) |
JP (1) | JP4309650B2 (zh) |
CN (1) | CN1315482C (zh) |
AT (1) | ATE315399T1 (zh) |
CA (1) | CA2423783C (zh) |
DE (1) | DE60116662T2 (zh) |
DK (1) | DK1320375T3 (zh) |
ES (1) | ES2252317T3 (zh) |
NO (1) | NO331751B1 (zh) |
WO (1) | WO2002026242A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104872457A (zh) * | 2015-06-23 | 2015-09-02 | 通威股份有限公司 | 一种提高罗非鱼抗链球菌能力的配合饲料 |
CN105124248A (zh) * | 2015-08-28 | 2015-12-09 | 通威股份有限公司 | 一种提高红罗非鱼抗病机能的配合饲料 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7431939B1 (en) | 2000-09-28 | 2008-10-07 | Mississippi State University | Inhibition of systemic infections in humans and vertebrates by dietary fibers |
US20040001898A1 (en) * | 2002-06-26 | 2004-01-01 | Armand Malnoe | Compositions and methods for detoxification and cancer prevention |
WO2007069900A1 (en) | 2005-12-16 | 2007-06-21 | N.V. Nutricia | Use of soluble dietary fibres against muscle wasting |
JP5264702B2 (ja) * | 2006-03-29 | 2013-08-14 | ネステク ソシエテ アノニム | プロバイオティクスを含有する栄養補助食品 |
US20090061008A1 (en) * | 2007-08-30 | 2009-03-05 | Levy Mark M | Fiber/granule complex for treatment of the gi tract |
CN102123715B (zh) | 2008-06-13 | 2014-12-17 | N.V.努特里奇亚 | 刺激免疫系统的营养物 |
US9491962B2 (en) * | 2010-06-30 | 2016-11-15 | Nestec S.A. | Use of chicoric acid and derivatives for regulating skin pigmentation |
WO2013121214A1 (en) | 2012-02-16 | 2013-08-22 | The University Of Nottingham | Reduction of gastrointestinal tract colonisation by campylobacter |
WO2013187755A1 (en) | 2012-06-14 | 2013-12-19 | N.V. Nutricia | Fermented infant formula with non digestible oligosaccharides |
CN107105749A (zh) | 2014-08-13 | 2017-08-29 | 阿克索生物医药公司 | 抗微生物化合物和组合物及其用途 |
WO2016207061A1 (en) * | 2015-06-23 | 2016-12-29 | Nestec S.A. | Nutritional compositions and infant formulas containing oligofructose for reducing the load of pathogenic bacteria in the guts of infants and young children |
CN107921058B (zh) * | 2015-08-04 | 2021-04-16 | 南方糖业股份公司 | 菊糖对鼻窦炎的预防作用 |
US10653658B2 (en) | 2015-08-11 | 2020-05-19 | Akeso Biomedical, Inc. | Biofilm inhibiting compositions enhancing weight gain in livestock |
PL3334440T3 (pl) | 2015-08-11 | 2021-11-02 | Akeso Biomedical, Inc. | Kompozycje hamujące tworzenie biofilmu wspierające przyrost masy ciała u zwierząt gospodarskich |
EP3207933A1 (en) * | 2016-02-17 | 2017-08-23 | Proponent Biotech GmbH | Uses of polyfructans |
BE1025705B1 (fr) * | 2017-09-12 | 2019-06-18 | Cosucra Groupe Warcoing Sa | Amélioration de la maladie et des conditions générales de la volaille et du bétail à l'aide d'une racine chicorée séchée |
US10842811B2 (en) * | 2018-02-28 | 2020-11-24 | The Trustees Of Columbia University In The City Of New York | Inulin for preventing antibiotic resistant infection and pathogen colonization |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0247071B1 (en) * | 1985-10-31 | 1993-09-22 | The Australian National University | Immunotherapeutic treatment |
US5032579A (en) | 1987-10-13 | 1991-07-16 | Coors Biotech, Inc. | Method for inhibiting the growth of salmonella |
DE69108846T2 (de) | 1990-10-24 | 1995-10-12 | Sandoz Nutrition Ltd | Vollwertnahrung aus hydrolysierten löslichen Faserstoffen. |
ES2060543B1 (es) * | 1993-03-26 | 1995-04-01 | Cia Gral Del Algarrobo De Espa | Fibra natural de algarroba y procedimiento para su obtencion. |
DE59409620D1 (de) | 1993-08-10 | 2001-02-01 | Suedzucker Ag | Verwendung von Inulinderivaten |
US6001878A (en) | 1994-01-11 | 1999-12-14 | Van Leeuwen; Paulus Aloisius Marie | Method of treating disorders of the animal or human body by administering amino acids |
US6241983B1 (en) * | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
EP0756828B2 (en) * | 1995-08-04 | 2010-09-22 | N.V. Nutricia | Nutritional composition containing fibres |
EP0879600A1 (en) * | 1997-05-20 | 1998-11-25 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Fructan containing composition for the prevention and treatment of colon cancer |
DK0887024T3 (da) | 1997-06-23 | 2004-09-27 | Nestle Sa | Ernæringssammensætning omfattende ærtefibre og inulin |
EP0904784A1 (en) | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
US6248375B1 (en) * | 2000-03-14 | 2001-06-19 | Abbott Laboratories | Diabetic nutritionals and method of using |
US7431939B1 (en) | 2000-09-28 | 2008-10-07 | Mississippi State University | Inhibition of systemic infections in humans and vertebrates by dietary fibers |
EP1428528A1 (en) | 2002-09-27 | 2004-06-16 | Tiense Suikerraffinaderij N.V. | Synergistic combinations of dietary fiber and NSAIDs for the treatment of cancer |
-
2000
- 2000-09-28 US US09/671,106 patent/US7431939B1/en not_active Expired - Lifetime
-
2001
- 2001-09-27 WO PCT/EP2001/011198 patent/WO2002026242A2/en active IP Right Grant
- 2001-09-27 ES ES01985674T patent/ES2252317T3/es not_active Expired - Lifetime
- 2001-09-27 CA CA002423783A patent/CA2423783C/en not_active Expired - Fee Related
- 2001-09-27 DE DE60116662T patent/DE60116662T2/de not_active Expired - Lifetime
- 2001-09-27 DK DK01985674T patent/DK1320375T3/da active
- 2001-09-27 CN CNB018165524A patent/CN1315482C/zh not_active Expired - Fee Related
- 2001-09-27 EP EP01985674A patent/EP1320375B1/en not_active Revoked
- 2001-09-27 JP JP2002530072A patent/JP4309650B2/ja not_active Expired - Fee Related
- 2001-09-27 AT AT01985674T patent/ATE315399T1/de not_active IP Right Cessation
-
2003
- 2003-03-19 NO NO20031259A patent/NO331751B1/no not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104872457A (zh) * | 2015-06-23 | 2015-09-02 | 通威股份有限公司 | 一种提高罗非鱼抗链球菌能力的配合饲料 |
CN105124248A (zh) * | 2015-08-28 | 2015-12-09 | 通威股份有限公司 | 一种提高红罗非鱼抗病机能的配合饲料 |
Also Published As
Publication number | Publication date |
---|---|
CA2423783A1 (en) | 2002-04-04 |
US7431939B1 (en) | 2008-10-07 |
EP1320375B1 (en) | 2006-01-11 |
NO20031259L (no) | 2003-05-07 |
DE60116662T2 (de) | 2006-11-09 |
WO2002026242A2 (en) | 2002-04-04 |
JP2004509922A (ja) | 2004-04-02 |
NO20031259D0 (no) | 2003-03-19 |
ES2252317T3 (es) | 2006-05-16 |
DE60116662D1 (de) | 2006-04-06 |
CN1315482C (zh) | 2007-05-16 |
JP4309650B2 (ja) | 2009-08-05 |
DK1320375T3 (da) | 2006-05-22 |
ATE315399T1 (de) | 2006-02-15 |
CA2423783C (en) | 2007-11-20 |
EP1320375A2 (en) | 2003-06-25 |
NO331751B1 (no) | 2012-03-19 |
WO2002026242A3 (en) | 2002-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1315482C (zh) | 膳食纤维对人和脊椎动物的全身性感染的抑制作用 | |
Shang et al. | Gut microbiota fermentation of marine polysaccharides and its effects on intestinal ecology: An overview | |
Sathyabama et al. | Co-encapsulation of probiotics with prebiotics on alginate matrix and its effect on viability in simulated gastric environment | |
DE602004006133T2 (de) | Neue galactooligosaccharidzusammensetzung und herstellung davon | |
Daniels et al. | Prebiotic applications in shellfish | |
KR102345546B1 (ko) | 소화 건강, 체중 조절, 면역 강화 및 건강 개선을 위한 다중섬유 프리바이오틱 제제 | |
CN105639631A (zh) | 含有非活的双歧杆菌和非消化性寡糖的营养物 | |
DE202016008919U1 (de) | Zusammensetzungen zur Verwendung bei der Prävention oder Behandlung von gastrointestinalen Infektionen/Entzündungen bei Säuglingen oder Kleinkindern | |
WO2017219106A1 (pt) | Composição imunomoduladora e promotora de crescimento e de controle da população de bactérias indesejáveis da microbiota intestinal e seu uso | |
TWI272914B (en) | Additives for crustacean or fish feeds and feeds | |
TW202408553A (zh) | 長雙歧桿菌過渡微生物之用途 | |
EP1633373B1 (en) | Pharmaceutical composition comprising glucan derived from microalgae | |
JPH0984529A (ja) | 微生物由来のマンナンを含む家畜および家禽用飼料 | |
Robinson et al. | Nutritional benefits of larch arabinogalactan | |
CN110664833A (zh) | 黄芪多糖壳聚糖纳米粒的制备方法及其用途 | |
WO2019046919A1 (pt) | Composição de aditivos prebióticos promotores de crescimento para rações animais e seu uso | |
JP5072286B2 (ja) | 動物の免疫調節剤 | |
Pluske et al. | Nutritional management of the gastrointestinal tract to reduce enteric diseases in pigs | |
Hadebe | Isolation and characterization of prebiotic oligosaccharides from algal extracts and their effect on gut microflora | |
US20240148778A1 (en) | Glycoside inhibitors of yeast | |
JP2004099580A (ja) | 免疫増強組成物並びにそれを含有する哺乳類、魚類用飼料 | |
JP2021514383A (ja) | サルモネラ症の予防又は治療に使用するための組成物 | |
CN113924107B (zh) | 用于预防单纯性和/或复发性膀胱炎的包含酵母的组合物 | |
WO2024068747A1 (en) | Uses of bifidobacterium longum transitional microorganism | |
WO2023281099A1 (en) | Uses of bifidobacterium longum transitional microorganism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070516 Termination date: 20180927 |
|
CF01 | Termination of patent right due to non-payment of annual fee |